We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
-7.72%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$157M
AUM Growth
+$31.7M
Cap. Flow
+$45.5M
Cap. Flow %
28.95%
Top 10 Hldgs %
45.06%
Holding
108
New
39
Increased
16
Reduced
23
Closed
22

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$8.9M
2
MA icon
Mastercard
MA
+$8.7M
3
FISV
Fiserv Inc
FISV
+$8.43M
4
PYPL icon
PayPal
PYPL
+$6.75M
5
FIS icon
Fidelity National Information Services
FIS
+$4.01M

Top Sells

Rank Stock Value
1
XLNX
Xilinx Inc
XLNX
+$5.13M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$4.35M
3
NUAN
Nuance Communications, Inc.
NUAN
+$3.59M
4
CONE
CyrusOne Inc Common Stock
CONE
+$3.47M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 44.39%
2 Technology 25.46%
3 Financials 19.54%
4 Consumer Discretionary 2.88%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.95B
$1.63M 1.03%
+168,691
New +$1.44M
RCUS icon
27
Arcus Biosciences
RCUS
$3.66B
$1.58M 1%
+50,050
New +$1.68M
AMRN
28
Amarin Corp
AMRN
$300M
$1.57M 1%
+23,837
New +$1.57M
BHVN
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.5M 0.96%
+12,678
New +$1.58M
NVCR icon
30
NovoCure
NVCR
$2.03B
$1.45M 0.92%
+17,448
New +$1.29M
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.11M 0.71%
+67,777
New +$922K
DBC icon
32
Invesco DB Commodity Index Tracking Fund
DBC
$1.72B
$1.1M 0.7%
42,396
– –
FOLD
33
DELISTED
Amicus Therapeutics
FOLD
$1.02M 0.65%
108,257
-5,130
-5% -$48.1K
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$982K 0.62%
53,164
+8,870
+20% +$151K
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$134B
$979K 0.62%
3,752
-1,383
-27% -$328K
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$8.95B
$971K 0.62%
44,226
-8,756
-17% -$177K
GHRS icon
37
GH Research
GHRS
$2.06B
$966K 0.61%
52,840
+25,830
+96% +$456K
ARGX icon
38
argenx
ARGX
$53.8B
$965K 0.61%
3,061
-2,501
-45% -$727K
GBIO
39
DELISTED
Generation Bio
GBIO
$964K 0.61%
+13,130
New +$761K
DICE
40
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$937K 0.6%
+48,960
New +$874K
ASND icon
41
Ascendis Pharma A/S
ASND
$16.7B
$918K 0.58%
7,821
-720
-8% -$83.4K
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$29.4B
$907K 0.58%
5,555
-1,538
-22% -$234K
VRDN icon
43
Viridian Therapeutics
VRDN
$2.68B
$907K 0.58%
+49,065
New +$943K
IOVA icon
44
Iovance Biotherapeutics
IOVA
$2.9B
$906K 0.58%
54,401
-12,238
-18% -$189K
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$902K 0.57%
53,583
-47,561
-47% -$703K
SRPT icon
46
Sarepta Therapeutics
SRPT
$1.9B
$884K 0.56%
+11,310
New +$866K
TCDA
47
DELISTED
Tricida, Inc. Common Stock
TCDA
$881K 0.56%
+107,202
New +$970K
CLDX icon
48
Celldex Therapeutics
CLDX
$3.49B
$877K 0.56%
25,738
-4,118
-14% -$132K
KROS icon
49
Keros Therapeutics
KROS
$212M
$872K 0.55%
+16,040
New +$823K
HZNP
50
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$869K 0.55%
8,256
-3,042
-27% -$296K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q1 2022 Portfolio in Review

As of Q1 2022, HighVista Strategies held 108 positions worth $157M, up 25% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

HighVista Strategies deployed $45.5M of net new capital in Q1 2022, opening 39 new positions and adding to 16 existing holdings. Its largest new stake was Visa: 41,135 shares worth $9.12M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $1.05M trimmed.

  • HighVista Strategies's largest Q1 2022 buy was Visa: 41,135 shares worth $9.12M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q1 2022, an estimated $1.72M increase.
  • HighVista Strategies's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $1.05M.
  • HighVista Strategies fully exited Xilinx Inc in Q1 2022, selling an estimated $5.13M.
  • HighVista Strategies's ten largest holdings make up 45% of its $157M portfolio in Q1 2022.
  • HighVista Strategies opened 39 new positions and closed 22 in Q1 2022.
  • HighVista Strategies's portfolio value rose 25% quarter-over-quarter to $157M.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.